COGNITION THERAPEUTICS INC. - COMMON STOCK

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes

01 Apr 2025 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025

25 Mar 2025 06:30:57 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

20 Mar 2025 06:00:26 By Nasdaq GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

13 Mar 2025 15:05:30 By Nasdaq GlobeNewswire

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

12 Mar 2025 15:05:04 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

10 Mar 2025 06:30:44 By Nasdaq GlobeNewswire

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

27 Feb 2025 06:30:08 By Nasdaq GlobeNewswire

Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy

26 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

25 Feb 2025 06:30:40 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)

20 Feb 2025 06:30:00 By Nasdaq GlobeNewswire

Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

30 Jan 2025 06:30:33 By Nasdaq GlobeNewswire

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

08 Jan 2025 15:14:32 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

18 Dec 2024 06:22:43 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

26 Nov 2024 06:30:22 By Nasdaq GlobeNewswire

Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population

25 Nov 2024 06:30:49 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

13 Nov 2024 06:30:45 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

12 Nov 2024 06:30:38 By Nasdaq GlobeNewswire

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

31 Oct 2024 15:15:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

29 Oct 2024 11:55:00 By Nasdaq GlobeNewswire

Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD

23 Oct 2024 06:30:27 By Nasdaq GlobeNewswire